摘要
目的 观察几种周剂昔紫杉醇化疗预处理方案的安全性和不良反应以及周剂量紫杉醇的近期疗效和毒副反应，探索最佳周剂量紫杉醇顶处理方法。方法 紫杉醇50～100mg／m^2，d1,8和（或）d15，联合铂类药物，每28天重复。采用4类预处理方式。结果 29例可评价疗效，其中：CR0例，PR9例，SD16例，PD4例。预处理相关的毒副反应：过敏反应；低钾血症；肌无力；呃逆；感染。结论 周剂量紫杉醇联合铂类药物治疗晚期非小细胞肺癌安全有效；推荐的周剂量紫杉醇化疗预处理方案为：紫杉醇化疗前12h及2h，口服地塞米松2．25～7．5mg，化疗前30min予止吐药、H2受体拮抗剂和抗组胺药。
Objective The purpose of this study was to evaluate the efficacy and safety of weekly Paclitaxel schedule in the treatment of advanced NSCLC and to obtain an optimal pre-medication protocol for weekly Paclitaxel. Methods Thirty four patients with advanced NSCLC were treated with Paclitaxel 50 - 100mg/m^2 by intravenous infusion for days 1, 8 and/or 15, combined with Oxaliplatin or Cisplatin. Each chemotherapy cycle was 28 days. Four pre-medications were adopted （detailed in the text）. Results Of the 29 eligible patients who completed at least 2 cycles, no patient had a complete response, 9 cases achieved a partial response, 4 cases showed progression. The limiting toxicity was myelosuppression. Toxicity profile of pre-medications included： hypersensitivity, hypopotassemia, myasthenia, hiccup, infection. Conclusions Weekly delivery of Paclitaxel/Docetaxel are a safe and active protocol for patients with advanced NSCLC. Our recommendable pre-medications are： Dexamethasone 2.25 - 7.5 mg orally 12h and 2h before Paclitaxel, antihistaminic and an H2-blocker 30 min before Paclitaxel.
出处
《肿瘤基础与临床》
2006年第5期369-371,共3页
journal of basic and clinical oncology
基金
江苏省人事厅"六大人材高峰"
项目江苏省肿瘤医院重点科研项目(编号:ZK200602)
关键词
非小细胞肺癌
紫杉醇
预处理
non-small cell lung cancer
Paclitaxel
pre-medication
